Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Johnson and Johnson
McKinsey
Healthtrust
AstraZeneca
Covington
Argus Health
Cerilliant

Generated: June 20, 2018

DrugPatentWatch Database Preview

Medimmune Oncology Company Profile

« Back to Dashboard

What is the competitive landscape for MEDIMMUNE ONCOLOGY, and what generic alternatives to MEDIMMUNE ONCOLOGY drugs are available?

MEDIMMUNE ONCOLOGY has one approved drug.

There is one US patent protecting MEDIMMUNE ONCOLOGY drugs.

There are six patent family members on MEDIMMUNE ONCOLOGY drugs in six countries.

Summary for Medimmune Oncology
International Patents:6
US Patents:1
Tradenames:1
Ingredients:1
NDAs:1
Patent Litigation for Medimmune Oncology: See patent lawsuits for Medimmune Oncology

Drugs and US Patents for Medimmune Oncology

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 DISCN No No 6,017,922 ➤ Try a Free Trial ➤ Try a Free Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 DISCN No No 6,017,922 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Medimmune Oncology

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 6,017,922 ➤ Try a Free Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 4,376,858 ➤ Try a Free Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 6,017,922 ➤ Try a Free Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 4,694,007 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Medimmune Oncology

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,258,952 Thermally stable trimetrexates and processes for producing the same ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Argus Health
Baxter
Accenture
Chinese Patent Office
Merck
Teva
Cerilliant
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.